The GSK3B Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the 143B human osteosarcoma cell line, featuring targeted gene disruption of GSK3B. This heterogeneous cell pool offers a loss-of-function model for interrogating GSK3B-mediated signaling networks without the biases introduced by clonal selection, enabling robust functional genomics and pathway analysis.
The 143B cell line serves as a well-established model of human osteosarcoma, originating from a bone tumor and retaining aggressive growth characteristics, metastatic potential, and key molecular alterations such as hyperactive Wnt/??-catenin and PI3K/AKT pathways. Its mesenchymal phenotype and tumorigenicity make it an ideal host for examining the role of GSK3B in bone cancer pathogenesis and therapy.
GSK3B is a constitutively active serine/threonine kinase that functions in a destruction complex with AXIN, APC, and CK1, phosphorylating ??-catenin to promote its proteasomal degradation. Upstream, AKT inactivates GSK3B via phosphorylation at Ser9, while WNT ligands through Frizzled receptors and DVL disrupt the complex, leading to ??-catenin stabilization and nuclear translocation. Active ??-catenin partners with TCF/LEF transcription factors to induce targets such as c-MYC and cyclin D1. GSK3B also integrates signals from insulin, PI3K/AKT, Hedgehog, and NF-??B pathways and interacts with regulators including PP2A, FRAT1, and DISC1.
In the 143B osteosarcoma context, GSK3B knockout generates a cellular environment of constitutive ??-catenin activation, mimicking the oncogenic Wnt signaling that drives tumor aggressiveness. This polyclonal knockout population enables dissection of ??-catenin-dependent transcriptional programs that influence cell cycle progression, apoptosis evasion, and migration, and facilitates assessment of the heterogeneity of Wnt pathway addiction. It also serves as a critical tool for validating GSK3B as a therapeutic target and evaluating the biological effects of pharmacological inhibitors.
These polyclonal knockout cells are optimized for diverse experimental workflows, including western blotting to confirm GSK3B ablation and monitor phospho-GSK3B (Ser9) and total ??-catenin levels, RT-qPCR to quantify Wnt target gene expression (c-MYC, cyclin D1), TOPFlash/FOPFlash luciferase reporters to measure TCF/LEF activity, and immunofluorescence to visualize ??-catenin nuclear localization. Functional characterization can be performed using MTS proliferation assays, Transwell migration/invasion experiments, and phospho-signaling analysis of the AKT pathway. The model is also suited for high-throughput screening of GSK3B inhibitor libraries. For further information or to discuss custom applications, please contact Ascent Research.
